BioWorld-International-2011-06-15
4SC Stock Plummets on Vidofludimus Miss in RA
4SC Stock Plummets on Vidofludimus Miss in RA
Shares in 4SC AG dropped 36 percent June 8 on news that its orally available drug vidofludimus missed the primary endpoint of a Phase IIb trial in rheumatoid arthritis, dashing investor hopes of a near-term deal. (BioWorld International)

